Form 4: Amicus Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Director Michael Raab exercised stock options to acquire 15,000 shares of Amicus Therapeutics common stock at $2.80 per share on March 5, 2024.
Summary
- On March 5, 2024, Michael Raab, a director of Amicus Therapeutics, Inc., exercised stock options.
- This transaction resulted in the acquisition of 15,000 shares of common stock at a price of $2.80 per share.
- Following the transaction, Raab directly owns 83,596 shares of Amicus Therapeutics common stock.
- The exercised stock options were fully vested and exercisable as of the transaction date.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a standard transaction (exercise of stock options) by a company director. It doesn't inherently indicate positive or negative implications for the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of transaction: Director exercised stock options and acquired common stock. |
| 03/06/2024 | Date of signature on the Form 4 filing. |
| 06/12/2024 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.